Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Solid Tumor 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Liver Neoplasms 2Liposarcoma 2Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Cancer × toripalimab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡